The use of a network medicine approach might result in innovative strategies for lowering coronary heart disease and CV risks

摘要

The reductionist approach of stringent guidelines for treating dyslipidemia led to significant lipoprotein transported cholesterol (LDLC) reduction with statin-based treatment to prevent or postpone development of atherosclerosis. Correct estimation of residual CV risk, however, remains a critical problem requiring the development of new integrated approaches Using a network-medicine approach might lead to creative methods. This is clearly a multidisciplinary technique that will be difficult in a clinical situation. To get a comprehensive picture of nodes and disease modules, we need to dissect a dyslipidemic patient to the level of single-cell analysis and then reconstruct the picture. These efforts are crucial to understanding the molecular networks that drive dyslipidemia and atherosclerosis. Moreover, in clinical assessment of persons with suspected coronary heart disease (CHD), computer-aided decision-making is more widespread. On the other hand, doctors should remember that robots lack a "sense of thinking" and should thus distrust the reliability of a purely robotic clinical decision. As a consequence, AI should be called "increased intelligence," which can help physicians make judgments but should keep the ultimate strategy in the physician's hands.